A STRATEGY FOR DETERMINING THE PATHOGENESIS OF SYSTEMIC SCLEROSIS: Is Transforming Growth Factor β the Answer?
- 1 July 1989
- journal article
- Published by Wiley in Arthritis & Rheumatology
- Vol. 32 (7), 817-825
- https://doi.org/10.1002/j.2326-5205.1989.tb00012.x
Abstract
No abstract availableThis publication has 51 references indexed in Scilit:
- Effect of lymphotoxin and tumor necrosis factor on endothelial and connective tissue cell growth and functionClinical Immunology and Immunopathology, 1988
- Tumor necrosis factor inhibits collagen and fibronectin synthesis in human dermal fibroblastsFEBS Letters, 1988
- Mononuclear cell-fibroblast interactions in sclerodermaClinical Immunology and Immunopathology, 1988
- Fibroblast Growth-Stimulatory Activity Released from Human Monocytes.Scandinavian Journal of Immunology, 1987
- Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease.The Journal of Experimental Medicine, 1987
- Elevated proα2(I) collagen mRNA levels in cultured scleroderma fibroblasts result from an increased transcription rate of the corresponding geneFEBS Letters, 1987
- TGF-β inhibition of endothelial cell proliferation: Alteration of EGF binding and EGF-induced growth-regulatory (competence) gene expressionCell, 1987
- Human monocyte modulation of endothelial cells and fibroblast growth: Possible mechanism for fibrosisClinical Immunology and Immunopathology, 1986
- Persistence of scleroderma‐like phenotype in normal fibroblasts after prolonged exposure to soluble mediators from mononuclear cellsArthritis & Rheumatism, 1986
- Host Immune Factors Regulating FibrosisPublished by Wiley ,1985